Eli Lilly and Company and Banner Alzheimerâs Institute have announced a strategic research collaboration as part of the planned Phase 3 study for donanemab in participants at risk from cognitive and functional decline related to Alzheimerâs disease.
Copyright © 2024 | WordPress Theme by MH Themes